InMed Reports Promising Alzheimer’s Drug Study Outcomes

InMed Pharmaceuticals (INM) has released an update.

InMed Pharmaceuticals revealed promising results from a long-term preclinical Alzheimer’s study of their drug candidate INM-901, which showed improvements in cognitive function, memory, and locomotor activity, and achieved statistical significance in behavioral assessments. These findings are consistent with and build upon earlier results from a short-term study, suggesting INM-901’s potential as an effective treatment for Alzheimer’s.

For further insights into INM stock, check out TipRanks’ Stock Analysis page.